Executive Director, Global Oncology Marketing, Breast Cancer

Merck•Rahway, NJ

1d•$255,800 - $402,700•Hybrid

About The Position

Within Human Health, the Executive Director, Global Oncology – Breast Cancer leads the global commercial strategy for the Breast cancer portfolio and partners with leaders across Women’s Cancers to shape a connected portfolio strategy. The role translates scientific innovation and clinical data into differentiated commercial strategies and value propositions, informed by customer, competitor, and standard-of-care insights. It also provides strategic partnership to asset teams and coordinates planning and execution across global, regional, and local organizations and functions. The Executive Director represents the commercial Breast cancer perspective in governance forums and cross-functional teams, contributes to portfolio and business development discussions, and drives disease-level initiatives that support the Breast cancer portfolio and wider Women’s Cancers franchise. The role also provides line leadership to global marketers and/or tumor leads, developing the team’s commercial and oncology capabilities and fostering collaboration, accountability, and innovation. This role reports to the Vice President, Women’s Cancers, sac-TMT and Early Commercial team. The position is based in Rahway, New Jersey, or Upper Gwynedd, Pennsylvania, with a hybrid work model and travel of up to 25%, including some international travel and occasional weekends as business needs require. The role is a regular employee position with a day shift. Relocation is available domestically or internationally; visa sponsorship is not available.

Requirements

Bachelor’s degree.
At least 12 years of experience in pharmaceutical or life science commercial roles, such as marketing, access, insights, or portfolio/brand management.
At least 2 of the required 12 years in marketing, emphasizing global marketing and complex scientific therapeutic areas and/or highly competitive markets.
Experience leading strategy development, portfolio/brand planning, and execution in a complex, highly regulated environment.
Team leadership experience, including direct line management and/or leadership of cross-functional teams.
Strong understanding of pharmaceutical market dynamics around the world, including the U.S. and key developed and emerging markets.
Ability to communicate complex scientific and business concepts effectively, including to senior leadership.
Strong problem-solving skills, analytical capability, and financial acumen, including forecasting, business cases, and investment decisions.
Track record of working effectively with cross-functional partners and creating alignment around strategic choices.
Demonstrated leadership and business acumen in oncology and/or specialty pharmaceutical markets.
Ability to articulate a vision for a complex global tumor area and translate it into strategies and execution plans.
Ability to lead teams through ambiguity and organizational change, with willingness to challenge the status quo.
Strong collaboration and influence skills across geographies, cultures, functions, and peer tumor teams.
Action- and solution-oriented approach with accountability for business outcomes.

Nice To Haves

MD, MSc, PhD, MBA, or another advanced degree in life sciences, business, or a related field.
Previous experience in oncology, especially Breast cancer or Gyn cancers, or related solid tumors.
Experience with global asset launch planning and execution, such as indication launches or label expansions.
Experience in an advanced operating role in market.
Experience working across multiple regions and cultures; additional language skills are a plus.

Responsibilities

Define and lead the global commercial strategy for current and future Breast cancer indications, aligned with and contributing to the broader Women’s Cancers strategy.
Translate scientific innovation and clinical data into differentiated value propositions and strategic frameworks, including Market Overviews and Assessments, Target Product Profiles, and forecasts.
Use insights into customers, competitors, and the evolving standard of care across Breast cancer subtypes to inform strategy.
Provide strategic partnership to asset teams on development and commercialization strategies.
Guide development and delivery of global sales forecasts for Breast cancer indications in collaboration with Asset Teams, Forecasting, and Finance.
Drive cross-functional and cross-regional alignment on key planning assumptions.
Partner with Gyn cancer portfolio leaders to share insights and best practices, align on common customers, platforms, and priorities, and coordinate resources and launch timing.
Partner with Global Market Access, Medical Affairs, Regulatory Affairs, Clinical Development, HEOR, Manufacturing, IP/Legal, Competitive Intelligence, and Finance to develop integrated strategies and execution plans.
Collaborate with Regional and Local Marketing Organizations so local market needs and insights inform global strategy and support in-market execution.
Represent the commercial Breast cancer perspective in internal governance forums and cross-functional asset and tumor teams, and contribute to Women’s Cancers discussions.
Contribute to portfolio and business development discussions, including assessment of external business development opportunities.
Identify and lead disease-level initiatives supporting the Breast cancer portfolio and collaborate on initiatives benefiting the wider Women’s Cancers franchise.
Provide leadership and line management to a team of global marketers and/or tumor leads supporting the Breast cancer portfolio.
Develop commercial competencies and oncology expertise across the team, including talent development and succession planning.
Champion effective ways of working and foster collaboration, accountability, and innovation within the team and across Women’s Cancers.
Manage strategic and operational issues related to access, supply, competitive response, and policy or environmental changes.
Communicate and align with senior leaders on risks, opportunities, and performance drivers in the Breast cancer business and its interdependencies across Women’s Cancers.